Chemotherapy-induced Neutropenia Treatment Market 2030: Navigating the Future of Oncology
The global chemotherapy-induced neutropenia (CIN) treatment market was valued at USD 1.63 billion in 2024 and is expected to decline to USD 1.51 billion by 2030, with a compound annual growth rate (CAGR) of -0.48% between 2025 and 2030. This projected decrease is largely influenced by regulatory challenges and pricing pressures in key markets, as governments and healthcare systems increasingly seek cost-effective treatment alternatives. Despite this anticipated downturn, notable opportunities remain within the CIN treatment sector. The ongoing development of innovative long-acting granulocyte colony-stimulating factors (G-CSFs) and next-generation biologics provides promising potential for growth, as these advancements aim to improve treatment effectiveness and patient adherence. A primary factor fueling the CIN treatment market is the rising global incidence of cancer. Cancer continues to be a leading cause of illness and death worldwide, with millions of new diagnoses each year. F...